Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by University Ghent
Agentschap voor Innovatie door Wetenschap en Technologie
Information provided by (Responsible Party):
University Ghent Identifier:
First received: September 11, 2008
Last updated: June 3, 2015
Last verified: June 2015
The purpose of this study is to assess the safety and the efficacy of vaginally administered probiotic lactobacilli in combination with antibiotic therapy (metronidazole) in women with microbiologically defined bacterial vaginosis.

Condition Intervention
Bacterial Vaginosis
Other: Probiotic lactobacilli
Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System

Resource links provided by NLM:

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • The proposed research project aims at the development of a vaginal probiotic delivery system to restore and to maintain the vaginal microflora [ Time Frame: 3 months ]

Estimated Enrollment: 206
Study Start Date: October 2008
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Probiotic lactobacilli
Other: Probiotic lactobacilli
Probiotic lactobacilli in combination with antibiotic therapy
Placebo Comparator: 2
Other: Placebo
Placebo in combination with antibiotic therapy


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Untreated Bacterial Vaginosis (BV) (asymptomatic or symptomatic) as diagnosed during the screening visit using Amsel criteria.
  • Otherwise healthy? pre-menopausal women between 18-50 years of age at date of screening.
  • Regular menstrual cycles (21-35 days) or amenorrheic for at least 3 months due to use of a long acting progestin or continuous use of oral contraceptives.
  • Subject is willing to insert vaginal applicators.
  • Subject is willing to be asked questions about personal medical health and sexual history
  • Normal Pap smear collected at the screening visit? If a subject's Visit 0 Pap smear result is any of the following, the person is ineligible for participation: ASC-US (atypical squamous cells of undetermined significance), AGC (atypical glandular cells), ASC-H (atypical squamous cells, cannot r/o high grade lesion), LSIL (low grade squamous intraepithelial lesions), HSIL (high grade squamous intraepithelial lesions), adenocarcinoma in situ, adenocarcinoma, squamous cell carcinoma in situ, squamous cell carcinoma or inadequate sample
  • Agree to be sexually abstinent 48 hours prior to Visit 1 (enrollment) until 48 hours after application of the study product and a second time after visit 2.
  • Agree to abstain from the use of any other intravaginal product (i.e., contraceptive creams, gels, foams, sponges, lubricants, douches, etc.) throughout the trial period.
  • Agree to use an adequate method of birth control for the duration of the study to avoid pregnancy. Acceptable methods include a history of tubal ligation, male partner with a vasectomy, a steroidal contraceptive (oral, patch, injectable or implantable), IUD (Paragard or Mirena), condoms or abstinence.
  • Subject must have access to functioning refrigerator.

Exclusion Criteria:

  • Urogenital infection at screening or within the 21 days prior to screening. This includes urinary tract infection, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis or Treponema pallidum. Subjects may be re-screened at least 21 days after the respective antibiotic or antifungal therapies have been completed.
  • History of recurrent genital herpes.
  • Diagnosis of N. gonorrhoeae, C. trachomatis, T. pallidum or T. vaginalis on two or more occasions during the six months prior to screening.
  • Pregnancy or within 2 months of last pregnancy (all subjects will have a urine pregnancy test prior to enrollment).
  • Lactation.
  • Vaginal or systemic antibiotic or antifungal therapy within 21 days of the Screening visit or within 4 months of Enrollment visit.
  • Investigational drug use within 4 months or 10 half-lives of the drug, whichever is longer, of enrollment visit. Planned investigational drug use while participating in this study.
  • Menopause.
  • IUD insertion or removal within the last 3 months.
  • Pelvic surgery within the last 3 months.
  • Cervical cryotherapy or cervical laser within the last 3 months.
  • Use of a NuvaRing® within 3 days of the screening visit or during the course of the study.
  • New long-acting treatments (e.g. depot formulation including medroxyprogesterone acetate (DMPA) form of hormonal birth control). Subjects may be enrolled if stable (> 3 months) on existing therapy as determined by the Principal Investigator.
  • Diabetes or other significant disease or acute illness that in the Investigator's assessment could complicate the evaluation.
  • Known HIV infection or positive HIV test at screening.
  • Immunosuppressive drug within 4 months.
  • Previous participation in a L. crispatus clinical study.
  • Colposcopic findings at the enrollment visit involving significant deep disruption of the epithelium.
  • Known allergy to any component (skim milk,…) of the drug or to latex (condoms).
  • Unavailable for follow-up visits.
  • History of drug or alcohol abuse.
  • At enrollment, have any social or medical condition, or psychiatric illness that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00752193

Contact: Marleen Temmerman, MD, PhD

University Hospital Ghent Recruiting
Ghent, Belgium, 9000
Principal Investigator: Marleen Temmerman, MD, PhD         
Sponsors and Collaborators
University Ghent
Agentschap voor Innovatie door Wetenschap en Technologie
Principal Investigator: Marleen Temmerman, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Ghent Identifier: NCT00752193     History of Changes
Other Study ID Numbers: 2008/438
Study First Received: September 11, 2008
Last Updated: June 3, 2015

Additional relevant MeSH terms:
Vaginosis, Bacterial
Bacterial Infections
Vaginal Diseases
Genital Diseases, Female processed this record on April 28, 2017